Betagenin and the Gut–Pancreas Axis: A Candidate Intestine-Derived Signal for β-Cell Function and Survival in Diabetes Mellitus
Metabolites · 11.11.2026 · 16 (11) · 877
DOI: 10.3390/metabo16110877 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabolites, online erschienen am 11.11.2026. Verfasst von Tomotaka Yokoo und 1 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Pancreatic β-cell dysfunction and progressive loss of functional β-cell mass are central features of both type 1 and type 2 diabetes mellitus, although the mechanisms driving β-cell failure differ between these disorders. Current glucose-lowering therapies improve glycemic control and reduce cardiometabolic risk but do not consistently restore endogenous β-cell mass in established diabetes mellitus. The gut–pancreas axis has traditionally been defined by the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). However, the intestine produces additional signals that may influence β-cell function, survival, and regenerative capacity. Betagenin is a recently identified intestine-derived peptide generated from the Tm4sf20 gene product. An approximately 10-kDa betagenin-immunoreactive peptide was detected in the circulation of wild-type mice. The initial study reported that betagenin enhanced glucose-stimulated insulin secretion (GSIS), increased cell-cycle-associated responses in β-cell models and islet preparations, and reduced β-cell apoptosis. Pharmacological evidence implicated MEK–ERK1/2 signaling in selected responses. In isolated human islets, betagenin enhanced GSIS and increased 5-ethynyl-2′-deoxyuridine (EdU) incorporation, although the identity and fate of EdU-positive cells remain unresolved. In streptozotocin-induced diabetic mice, administration of synthetic betagenin and adenovirus-mediated betagenin expression improved hyperglycemia and were associated with recovery of estimated β-cell mass. These findings are preclinical; responses in isolated human islets do not establish clinical efficacy in patients or durable regeneration of functional human β-cells. This review examines betagenin as a candidate circulating component of the gut–pancreas axis and discusses its potential to influence β-cell function, survival, and recovery after injury. We also address key questions concerning physiological regulation of endogenous betagenin, receptor identification, β-cell specificity in human islets, pharmacokinetics, long-term safety, and therapeutic relevance in progressive type 2 diabetes mellitus.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Yokoo, T., & Toyoshima, H. (2026). Betagenin and the Gut–Pancreas Axis: A Candidate Intestine-Derived Signal for β-Cell Function and Survival in Diabetes Mellitus. Metabolites, 16(11), 877. https://doi.org/10.3390/metabo16110877
Vancouver
Yokoo T, Toyoshima H. Betagenin and the Gut–Pancreas Axis: A Candidate Intestine-Derived Signal for β-Cell Function and Survival in Diabetes Mellitus. Metabolites. 2026;16(11):877. doi:10.3390/metabo16110877
BibTeX
@article{Yokoo2026,
author = {Yokoo, Tomotaka and Toyoshima, Hideo},
title = {Betagenin and the Gut–Pancreas Axis: A Candidate Intestine-Derived Signal for β-Cell Function and Survival in Diabetes Mellitus},
journal = {Metabolites},
year = {2026},
volume = {16},
number = {11},
pages = {877},
doi = {10.3390/metabo16110877}
}
EUVIMED